Novel In-Clinic Use of Levodopa Inhalation Powder (CVT-301) as an Outpatient Diagnostic Tool for Parkinson's disease (PD)

被引：0
|
作者：
Afshari, Z.
Nguyen, N.
Afshari, M.
机构：
来源：
MOVEMENT DISORDERS | 2024年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
817
引用
收藏
页码：S368 / S368
页数：1
相关论文
共 50 条
  • [1] Dyskinesia Rates in Patients with Parkinson's Disease on CVT-301 (levodopa inhalation powder)
    Pourcher, E.
    Corbin, A.
    Qian, J.
    Kenney, C.
    MOVEMENT DISORDERS, 2019, 34
  • [2] CVT-301 (Levodopa Inhalation Powder): Meta-Analysis of Safety in Patients With Parkinson's Disease (PD)
    LeWitt, Peter
    Zhao, Ping
    Corbin, Ann
    Kegler-Ebo, Deena
    Blank, Burkhard
    NEUROLOGY, 2021, 96 (15)
  • [3] CVT-301 (levodopa inhalation powder): meta-analysis of safety in patients with Parkinson's disease (PD)
    LeWitt, P.
    Zhao, P.
    Corbin, A.
    Kegler-Ebo, D.
    Blank, B.
    MOVEMENT DISORDERS, 2021, 36 : S183 - S183
  • [4] Efficacy of CVT-301 (levodopa inhalation powder) for treatment of OFF periods in Parkinson's disease
    Pahwa, R.
    Abeynayake, I.
    Klingler, M.
    Sedkov, A.
    Kenney, C.
    Oh, C.
    MOVEMENT DISORDERS, 2018, 33 : S164 - S164
  • [5] CVT-301 (Inhaled Levodopa) Utilization by Patients With Parkinson's Disease (PD) in Clinical Studies
    Ondo, William
    Saint-Hilaire, Marie-Helene
    Klingler, Michael
    Kenney, Christopher
    NEUROLOGY, 2020, 94 (15)
  • [6] CVT-301 for the treatment of Parkinson's disease
    Shpiner, Danielle S.
    Bette, Sagari
    Di Luca, Daniel G.
    Margolesky, Jason
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2019, 19 (07) : 603 - 611
  • [7] A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease
    LeWitt, Peter A.
    Hauser, Robert A.
    Grosset, Donald G.
    Stocchi, Fabrizio
    Saint-Hilaire, Marie-Helene
    Ellenbogen, Aaron
    Leinonen, Mika
    Hampson, Neil B.
    DeFeo-Fraulini, Tia
    Freed, Martin I.
    Kieburtz, Karl D.
    MOVEMENT DISORDERS, 2016, 31 (09) : 1356 - 1365
  • [8] Safety results of a 12-month, dose-level blinded study of CVT-301 (levodopa inhalation powder) in patients with Parkinson's disease
    Hauser, R. A.
    Waters, C. H.
    Lew, M.
    Farbman, E. S.
    Klingler, M.
    Oh, C.
    MOVEMENT DISORDERS, 2019, 34 : S3 - S3
  • [9] CVT-301 (levodopa inhalation powder) improves Patient Global Impression of Change (PGIC) over 1 year in patients with Parkinson's disease (PD): a meta-analysis
    Saint-Hilaire, M.
    Corbin, A.
    Zhao, P.
    Kegler-Ebo, D.
    MOVEMENT DISORDERS, 2021, 36 : S193 - S193
  • [10] Efficacy results of a 12-month, dose-level blinded study of CVT-301 (levodopa inhalation powder) in patients with Parkinson's disease
    Farbman, E. S.
    Lew, M.
    Waters, C. H.
    Hauser, R. A.
    Klingler, M.
    Oh, C.
    MOVEMENT DISORDERS, 2019, 34 : S17 - S17
12345